TNF and dermatomyositis: The strength of our work is to summarize the information published about the new onset of DM/PM during anti-TNF-α therapies, a particularly interesting fact in the daily clinical routine because there is evidence for anti-TNF-α therapies (case series and one RCT) and many physicians used such molecules as steroid sparing agents in patients affected by DM/PM [13, 45–59].